INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

REFERENCIAS BIBLIOGRÁFICAS
346. Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP,
Zabalgoitia M, Huynh T, Cuddy TE, Gersh BJ, Rouleau J, Braunwald E, Pfeffer MA;
PEACE Investigators. Predictors of heart failure in patients with stable coronary artery
disease: a PEACE study. Circ Heart Fail. 2009 May;2(3):209-16.
347. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial
stiffening of aging and diabetes. J Hypertens. 2003 Jan;21(1):3-12.
348. Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S,
Hirata K, Hayashi Y. RAGE mediates oxidized LDL-induced pro-inflammatory effects and
atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res. 2009 May
1;82(2):371-81.
349. Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, Brasacchio D,
Paavonen K, Chin-Dusting J, Cooper ME, Kaye D, Thomas MC, Forbes JM. Advanced
glycation end-products induce vascular dysfunction via resistance to nitric oxide and
suppression of endothelial nitric oxide synthase. J Hypertens. 2010 Apr;28(4):780-8.
350. Kamioka M, Ishibashi T, Sugimoto K, Uekita H, Nagai R, Sakamoto N, et al. Blockade of
renin-angiotensin system attenuates advanced glycation end products-mediated signaling
pathways. J Atheroscler Thromb. 2010 Jun 30;17(6):590-600.
351. Kamioka M, Ishibashi T, Sugimoto K, Uekita H, Nagai R, Sakamoto N, Ando K, Ohkawara H,
Teramoto T, Maruyama Y, Takeishi Y. Blockade of angiotensin II receptors reduces the
expression of receptors for advanced glycation end products in human endothelial cells.
Arterioscler Thromb Vasc Biol. 2006;26(10):e138-42.
352. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S,
Imaizumi T. Olmesartan blocks advanced glycation end products (AGEs)-induced
angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc
Res. 2008 Jan;75(1):130-4.
353. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation
end products activate a chymase-dependent angiotensin II-generating pathway in
diabetic complications. Circulation. 2006 Mar 14;113(10):1353-60.
354. Rodiño Kostka, BK. Efectos moleculares de los productos finales de glicación avanzada en
la célula endotelial humana (tesis doctoral). Directores: Ezequiel Álvarez Castro, José
Ramón González Juanatey. Universidad de Santiago de Compostela, 2011.
355. Han Y, Randell E, Vasdev S, Gill V, Curran M, Newhook LA, Grant M, Hagerty D, Schneider
C. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is
elevated in young, complication-free patients with Type 1 diabetes. Clin Biochem. 2009
May;42(7-8):562-9.
356. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M,
Hanssen KF. Increased serum levels of the specific AGE-compound methylglyoxalderived
hydroimidazolone in patients with type 2 diabetes. Metabolism. 2003
Feb;52(2):163-7.
357. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini
E, Gastaldelli A. Circulating soluble receptor for advanced glycation end products is
inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab.
2006 Nov;91(11):4628-34.
358. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and
diabetic vascular complications. Curr Diabetes Rev. 2005 Feb;1(1):93-106. Review.
359. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic
vascular complications. Physiol Res. 2004;53(2):131-42. Review.
360. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD;
EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE
are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this
association is partially mediated by endothelial and renal dysfunction and by low-grade
inflammation: the EURODIAB Prospective Complications Study. Diabetologia. 2009
Apr;52(4):705-14.
245